# LIGUE PULMONAIRE NEUCHATELOISE

## Introduction

COPD is an important cause of morbidity and mortality in the general population<sup>1</sup>. The prevalence of COPD in the general population varies from country to country depending on smoking habits and age distribution. The prevalence of bronchial obstruction in Switzerland is similar to that of European countries (8% in > 70-year-old patients, 29.3% of whom are non-smokers)<sup>2</sup>. The estimated number of COPD patients is about 400'000 in Switzerland<sup>3</sup>. Paradoxically, COPD remains underdiagnosed by doctors <sup>2-4</sup>. The term COPD is poorly known in Europe, Latin America and Asia, as less than 10% of the general population recognizes it 5-11. The aim of this study was to estimate the knowledge of COPD in a population of patients > 45 years old receiving home care in a semi-urban area (Canton of Neuchâtel, *fig. 1*). This study is part of a project aimed at increasing awareness among the general population, general practitioners and caregivers of the main home care institution on COPD in the canton of Neuchâtel.

### Methods

This was an observational, cross-sectional study conducted in November 2016 in the Canton of Neuchâtel. A questionnaire developed by La Ligue Pulmonaire Suisse to detect COPD (COPD risk test, fig. 2) in the general population based on smoking habits, symptoms of COPD (cough, sputum, wheezing, dyspnea) and history of asthma was offered to all patients aged over 45 and receiving home care through caregivers of a public home care institution (NOMAD) during 3 consecutive weeks. In addition, all patients were asked if they were familiar with the term COPD and/or emphysema and if they already had a spirometry. Weight, size, SpO<sub>2</sub> and the use of inhaled medication or oxygen were also recorded. All caregivers (240 people) of NOMAD involved in the study received prior training on COPD and smoking cessation counselling. Frequencies were obtained of the categorical variables, while in the continuous variables central tendency (mean) and dispersion (standard deviation) were evaluated. The Chi-squared test was used to analyse the relationship between categorical variables. For the continuous variables, ANOVA was used in comparisons of three or more groups. A p value of <0.05 was considered statistically significant.

Do you smoke or have you smoked ?	Yes (5 pts)	No (0 pts)	Group 1	0 pts	You are not in the risk group for COPD.
Do you cough, even if you have no cold?	Yes (5 pts)	No (0 pts)			Your risk of COPD is minimal. If you are still worried, talk to your
When you cough in the morning, do you produce some mucus?	Yes (5 pts)	No (0 pts)	Group 2	2-4 DIS	doctor.
Are you panting when climbing stairs or walking fast?	Yes (2 pts)	No (0 pts)		5 1 2 4	At the next visit, ask your doctor if you need further tests to determine
Do you wheeze?	Yes (2 pts)	No (0 pts)	Group 3	$n_1/n_1$	the risk of COPD.
Are you over 45 years old ?	Yes (2 pts)	No (0 pts)		14.02.44	There is a risk that you are suffering from COPD. We advise you to
Have you been diagnosed with asthma?	Yes (2 pts)	No (0 pts)	Group 4	14 - 73 nts	seek medical advice

#### Results

Out of a total of 724 participants, 639 (88.3 %) accepted to participate. We retained 444 (69.5 %) complete questionnaires.

Characteristics of participants (n=444)				
Sex, men / women n (%)	157/287 (35/65)			
Age, years (SD)	80 (11.1)			
BMI, kg/m <sup>2</sup> (SD)	26 (5.5)			
Smokers n (%)	68 (15.3)			
Ex-smokers n (%)	139 (31.3)			
Non-smokers (%)	237 (53.4)			
Inhaled treatment n (%)	55 (12)			
Oxygenotherapy n (%)	24 (5.4)			
Ever had a spirometry n (%)	104 (23)			
Recognition of « COPD » n (%)	40 (9.0)			
Recognition of « emphysema » n (%)	108 (24)			
COPD risk group 4 (%)	62 (14 %)			

# **COPD** knowledge in a swiss frail selected population G. Clark, D. Monnin, M. Marechal, Ligue Pulmonaire Neuchâteloise (Switzerland)




Figure 2: COPD risk test developed by la Ligue Pulmonaire Suisse

Repartition according to COPD risk group	COPD r	p¶		
	1-2 (188)	3 (194)	4 (62)	
ex, men (%)	41 (21.8)	85 (43.8)	31 (53)	<0.001¶
ge, years n (SD)	83 (9.6)	79 (10.8)	75 (13.7)	<0.001†
SMI, kg/m² n (SD)	25.8 (5.4)	26.1 (5.5)	26.6 (5.9)	0.601†
mokers n (%)	0	43 (22.2)	25 (40.3)	<0.05
x-smokers (%)	0	110 (56.7)	29 (46.7)	<0.05
lon-smokers (%)	188 (100)	41 (21.1)	8 (12.9)	<0.05
nhaled treatment (%)	5 (2.7)	25 (12.9)	25 (40.3)	<0.001¶
ver had a spirometry n (%)	29 (15.4)	55 (28.3)	20 (32.3)	0.003¶
Oxygenotherapy n (%)	8 (4.3)	8 (4.1)	8 (12.9)	0.019¶

¶ Chi-square test. † ANOVA for continuous variables.

# Results

Average age of patients was  $80 \pm 11.1$  with a minority of men (35%). Patients in COPD risk group 4 were statistically younger than in group 1-2 ( $75 \pm 13.7$  vs  $83 \pm 9.6$ ). Smokers represented 15% of patients. Men were more common in group 4 than women (53 vs 47%). In group 4, 32.3% of patients had spirometry and 40.3 % of patients were treated with inhaled drugs. In total, only 9% of patients were familiar with the term "COPD" compared to 24% for the term "emphysema". There was no difference between men and women, COPD risk group or having had spirometry in regard of recognition of « COPD » and « emphysema » terms. Only patients with inhaled therapy, smokers and ex-smokers were more familiar with the term « COPD » than people without such treatment. Overall, smokers and ex-smokers had more respiratory symptoms than nonsmokers (cough, sputum, wheezing) and a history of asthma. Only dyspnea was equivalent in 3 groups. The increasing of body mass index correlates with dyspnoea (p<0.001) and wheezing (p<0.001).

COPD

**Ever ha** Inhaled

## Conclusions

In this elderly population requiring home care, knowledge of both terms « COPD » and emphysema is poor and very close to what can be observed in younger populations in other countries of the world<sup>5-11</sup>. The low proportion of patients at high risk of COPD who had benefited of spirometry or inhaled treatment probably also reflects the lack of knowledge of the disease by the medical profession. Interestingly, patients at high risk of COPD were younger, but needed home care anyway. This may pinpoint the impact of respiratory symptoms on morbidity and autonomy. Smoking is accompanied by a significant increase in respiratory symptoms in this population. Dyspnea affects nearly 50% of smokers and non-smokers, which is probably indicative of associated co-morbidities. To improve the management of COPD in this population, it is important to continue raising awareness among patients, caregivers and physicians.

#### Bibliography

- http://www.who.int/respiratory/copd/burden/en/
- 2. Bridevaux PO. Prevalence of airflow obstruction in smokers and never-smokers in Switzerland. Eur Respir J 2010;36:1259–1269.
- Bednarek M. Pevalence, Severity and underdiagnosis of COPD in the primary care setting. Thorax 2008; 63:402–407. 2015;46(suppl 59):PA3867.
- 6. Sayiner A. Attitudes and beliefs about COPD: Data from the BREATHE study. Respiratory Medicine 2012;106(S2), S60–S74
- Miravitlles M. Chronic respiratory symptoms, spirometry and knowledge of COPD among general population. Respiratory Medicine 2006; 100:1973–1980. 8. Soriano JB. The General Public's Knowledge of Chronic Obstructive Pulmonary Disease and Its Determinants: Current Situation and Recent Changes. Arch Bronconeumol. 2012;48(9):308–315.
- 9. Hernandez P. Living with chronic obstructive pulmonary disease: A survey of patients' knowledge and attitudes. Respiratory Medicine 2009;103:1004e1012.
- 10. Mun S. Awareness of chronic obstructive pulmonary disease in current smokers: a nationwide survey. Korean J Intern Med 2015;30:191-197.
- 11. de Castro M. Knowledge about COPD among users of primary health care services. International Journal of COPD 2015;10 :1-6.

#### Acknowledgment • M. Bader, NOMAD (Neuchâtel Organise le Maintien à Domicile), all NOMAD caregivers.

- Mrs Barbosa, Mrs Chaillan, Mrs Bourquin, Ligue Pulmonaire NE.
- Société Neuchâteloise de Médecine
- M. Vuistiner, scientific collaborator, SUVA





ognition of COPD and Empysema	n	Recognition of « COPD »	p¶	Recognition of « emphysema »	р¶
risk group			0.238		0.212
Group 1-2 n (%)	188	14 (7.4)		38 (20.2)	
Group 3 n (%)	194	17(8.8)		54 (27.8)	
Group 4 n (%)	62	9 (14.5)		16 (25.8)	
ng status			0.021		0.072
Non-smoker n (%)	237	16 (6.8)		53 (22.3)	
Ex-smoker n (%)	139	12 (8.6)		31 (22.3)	
Smoker n (%)	68	12 (17.7)		24 (35.3)	
ad a spirometryn (%)	108	15 (14.4)	0.068	33 (31.7)	0.066
d therapy n (%)	40	10 (18.1)	0.011	16 (29.1)	0.379

¶ chi-square test : p value calculated according to answer « no » at the question recognition of term « COPD or « emphysema ».

Symptoms	Non-smokers (n =237)	Ex-smokers (n= 139)	Smokers (n= 68)	р¶
Cough (%)	31 (13.1)	28 (20.1)	26 (38.2)	<0.001
Sputum (%)	24 (10.1)	22 (15.8)	20 (29.4)	<0.001
Dyspnea (%)	114 (48.1)	60 (43.2)	30 (44.1)	0.616
Wheezing (%)	14 (5.9)	17 (12.2)	10 (14.7)	0.029
Asthma history (%)	6 (2.5)	11 (7.9)	11 (16.2)	<0.001

¶ chi-square test : difference between groups.

Stolz D. Diagnosis, Prevention and Treatment of Stable COPD and Acute Exacerbations of COPD: The Swiss Recommendations 2018. Respiration 2018;23:1-17. 5. Abu Hussein N. GPs based Swiss chronic obstructive pulmonary disease (COPD) cohort: disease management in primary care: descriptive data. Eur Respir J